TO: CITY EDITORS
FOR IMMEDIATE RELEASE
27 August, 2008

BIOQUELL PLC
2008 interim results

BIOQUELL PLC (“BIOQUELL”), the UK leader in specialist decontamination technology and testing / compliance services, announces its interim results for the six months ended 30 June 2008.  The highlights are:

• Revenues of £17.2m (2007: £15.8m) – increase of 9%
• Decontamination revenues of £11.8m (2007: £10.5m) – increase of 12%; TRaC revenues of £5.4m (2007: £5.3m) – increase of 2%
• Profit before tax of £2.4m (2007: £2.0m) – increase of 20%
• Earnings of £1.8m (2007: £1.7m) – increase in tax charge to 22% (2007: 13%)
• Net cash £4.1m (2007: £1.6m), comprising cash of £5.6m and debt of £1.5m
• Substantial increase in revenues from the Group’s hydrogen peroxide vapour (“HPV”) decontamination technology – from both the life sciences and healthcare sectors
• BIOQUELL’s HPV technology selected to participate in the UK Department of Health’s Showcase Hospitals programme
• Recent US scientific publication reports the use of BIOQUELL’s HPV technology in a US hospital to reduce the infection rate associated with the “superbug” Clostridium difficile 
• BIOQUELL proactive in-situ service decontamination teams now at 12 hospitals (2007: 1 hospital) in the US and the UK
• Defence revenues benefited from UK and Middle Eastern contracts, which offset the expected decline in MRAP-related revenues, as well as development work involving
• BIOQUELL’s HPV technology for the US Department of Defense’s Joint Materials Decontamination System programme
• Successful move of the Group’s head office and principal operating subsidiary to a newly renovated facility

Commenting on the interim results, John Salkeld, Chairman of BIOQUELL PLC said:
“We are pleased with the substantial increase in revenues, comprising both equipment sales and service decontamination, from BIOQUELL’s unique hydrogen peroxide vapour decontamination (“HPV”) technology. As expected, defence sector revenues declined in the period – but the decline was more than offset by growth in HPV revenues from the life sciences and healthcare sectors. The Group is delighted to be participating in the Department of Health’s Showcase Hospital Programme where our new technology - with its proven efficacy against “superbugs” - is being tested. We are also pleased with the strength of our balance sheet which includes net cash of £4.1million.”

To read the full annoucement and download as a PDF, Click here...

Enquiries:
John Salkeld BIOQUELL PLC 01264 835 900 
Nick Adams
Mark Bodeker